Cargando…

Composite outcomes in observational studies of Crohn’s disease: a systematic review and meta-analysis

BACKGROUND: This systematic review and meta-analysis aims to assess composite and aggregate outcomes of observational studies in Crohn’s disease and to evaluate whether the number and type of variables included affect the frequency of the outcome. METHODS: MEDLINE [via PubMed], Scopus and Web of Sci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magro, Fernando, Sottomayor, Catarina, Alves, Catarina, Santiago, Mafalda, Ministro, Paula, Lago, Paula, Correia, Luís, Gonçalves, Raquel, Carvalho, Diana, Portela, Francisco, Dias, Cláudia Camila, Dignass, Axel, Danese, Silvio, Peyrin-Biroulet, Laurent, Estevinho, Maria Manuela, Leão Moreira, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118904/ https://www.ncbi.nlm.nih.gov/pubmed/35601803 http://dx.doi.org/10.1177/17562848221092754

Ejemplares similares

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

Thiopurines’ Metabolites and Drug Toxicity: A Meta-Analysis
por: Sousa, Paula, et al.
Publicado: (2020)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale
por: Santiago, Mafalda, et al.
Publicado: (2019)

Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence
por: Santiago, Mafalda, et al.
Publicado: (2020)

Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study
por: Santiago, Mafalda, et al.
Publicado: (2020)

Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
por: Santiago, Mafalda, et al.
Publicado: (2022)

The risk of disabling, surgery and reoperation in Crohn’s disease – A decision tree-based approach to prognosis
por: Dias, Cláudia Camila, et al.
Publicado: (2017)

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
por: Magalhaes, Diogo, et al.
Publicado: (2023)

A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
por: Estevinho, Maria Manuela, et al.
Publicado: (2022)

Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?
por: Ministro, Paula, et al.
Publicado: (2021)

Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays
por: Rocha, Cátia, et al.
Publicado: (2020)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Not Everything That Ulcerates Is Crohn's Disease
por: Afecto, Edgar, et al.
Publicado: (2022)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Can we change the natural course of inflammatory bowel disease?
por: Le Berre, Catherine, et al.
Publicado: (2023)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
por: Spadaccini, Marco, et al.
Publicado: (2017)

The day after COVID-19 in IBD: how to go back to ‘normal’
por: Danese, Silvio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7r8hpfg9bg3jkavu1se5n7qejs